Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Androgen deprivation therapy Stories

2014-02-06 08:28:18

TORONTO, Feb. 6, 2014 /CNW/ - Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec now have access to a therapy that can be used prior to chemotherapy. Effective February 3, 2014, the province has added ZYTIGA(®) (abiraterone acetate) to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).(1) "ZYTIGA(® )provides men and health care professionals with a...

2014-01-24 13:33:49

No meaningful decline in emotional quality of life 2 years after therapy, reports the Journal of Urology A new study published in the Journal of Urology® reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment. Investigators at the University of California-San Francisco recommend counseling...

2013-11-21 12:27:51

TORONTO, Nov. 21, 2013 /CNW/ - Effective November 15, 2013, British Columbia is the first province to include ZYTIGA(®) (abiraterone acetate) on its public formulary for men living with metastatic prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).(1) Men living with advanced prostate cancer, their caregivers and health care professionals are encouraged to learn more about the specific eligibility criteria that are...

2013-07-16 22:34:28

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of ADTs, according to a study in the July 17 issue of JAMA. "Androgen deprivation therapy is the mainstay treatment for patients with advanced prostate cancer. While this therapy has been traditionally reserved for patients with advanced disease, ADT...

2013-05-30 10:46:24

Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia. Published today in Science Translational Medicine, a study led by Monash University researchers has found prostate cancer cells that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease...

2013-04-08 08:25:14

DETROIT, April 8, 2013 /PRNewswire-USNewswire/ -- Ulka Vaishampayan, M.D., leader of the Genitourinary Oncology Multidisciplinary Team at the Barbara Ann Karmanos Cancer Center, has contributed to an article just published in The New England Journal of Medicine comparing two different therapeutic methods in the treatment of metastatic, hormone-sensitive prostate cancer that becomes unresponsive to traditional methods of therapy. (Logo: http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO)...

2013-04-04 11:36:12

Large, international trial finds intermittent androgen deprivation is not equivalent to continuous treatment Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds. Based on previous smaller studies, it looked like an approach called intermittent androgen deprivation therapy might be just as good as continuous androgen deprivation in terms of survival...